menu
    • menu

    Company profile for Hansa Biopharma

    NEW Drugs in Dev: 4
    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Sigma-Aldrich empowers scientific discovery with top-quality solutions to accelerate research, innovation, and better health worldwide.

    Virtual Booth

    Contact Supplier

    Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.

    Virtual Booth

    Contact Supplier

    TransoPharm USA works in the Sourcing and Management of Active Pharmaceutical Ingredients.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Hansa Biopharma is leveraging its proprietary enzyme technology platform to develop immunomodulatory treatments for rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection and cancer. The Company’s lead product candidate, imlifidase, is an antibody-cleaving enzyme being developed to enable kidney transplantation in highly sensitized patients and may be further developed for use in other organ and ...
    Hansa Biopharma is leveraging its proprietary enzyme technology platform to develop immunomodulatory treatments for rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection and cancer. The Company’s lead product candidate, imlifidase, is an antibody-cleaving enzyme being developed to enable kidney transplantation in highly sensitized patients and may be further developed for use in other organ and tissue transplantation and acute autoimmune indications. Imlifidase is currently under review for a potential marketing authorization by European Medicines Agency (EMA).

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Hansa BiopharmaSweden Flag
    Country
    Country
    Sweden
    Address
    Address
    Hansa Biopharma AB P.O. Box 785 SE-220 07 Lund
    Telephone
    Telephone
    +46 46 16 56 70
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.hansabiopharma.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    IMCAS Asia

    IMCAS Asia

    Not Confirmed

    envelop Contact Supplier

    IMCAS Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Hansa Biopharma Reports Positive Idefirix Post-Auth Study
    Hansa Biopharma Reports Positive Idefirix Post-Auth Study

    27 May 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/hansa-biopharma-reports-positive-efficacy-and-safety-results-from-idefirix-european-post-authorization-study-in-kidney-transplantation-302782744.html

    PR NEWSWIRE
    27 May 2026
    Share Share
    Hansa Biopharma's ConfIdeS Phase 3 Abstract Selected at ATC 2026
    Hansa Biopharma's ConfIdeS Phase 3 Abstract Selected at ATC 2026

    25 May 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/hansa-biopharma-announces-late-breaking-abstract-from-confides-phase-3-trial-selected-for-oral-presentation-at-atc-2026-302781432.html

    PR NEWSWIRE
    25 May 2026
    Share Share
    SERB Acquires Idefirix European Rights from Hansa for €115M
    SERB Acquires Idefirix European Rights from Hansa for €115M

    19 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/19/3297132/0/en/serb-pharmaceuticals-to-acquire-european-and-mena-rights-to-idefirix-imlifidase-from-hansa-biopharma-for-115-million.html

    GLOBENEWSWIRE
    19 May 2026
    Share Share
    Hansa Biopharma Licenses IDEFIRIX to SERB for €115M
    Hansa Biopharma Licenses IDEFIRIX to SERB for €115M

    19 May 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/hansa-biopharma-enters-into-115-million-licensing-agreement-with-serb-pharmaceuticals-for-idefirix-in-europe-and-mena-302775762.html

    PR NEWSWIRE
    19 May 2026
    Share Share
    Full-Life Raises $150M; Quince Reboots with Pulmonary Drug
    Full-Life Raises $150M; Quince Reboots with Pulmonary Drug

    19 May 2026

    // ENDPOINTS

    https://endpoints.news/full-life-technologies-raises-150m-quince-finds-a-new-life/

    ENDPOINTS
    19 May 2026
    Share Share
    Hansa Biopharma Publishes 2025 Annual And Sustainability Reports
    Hansa Biopharma Publishes 2025 Annual And Sustainability Reports

    26 Mar 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-03-26/hansa-biopharma-publishes-2025-annual-and-sustainability-reports

    PHARMIWEB
    26 Mar 2026
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search